Close Menu

NEW YORK – GenMark Diagnostics reported after the close of the market on Monday a 23 percent increase in second quarter revenues, driven by strong placements of its ePlex analyzer.

Separately, the company said in a filing with the US Securities and Exchange Commission that it has entered into an equity distribution agreement with Canaccord Genuity relating to shares of the diagnostic firm's common stock. Under the terms of the agreement, GenMark may offer and sell shares of its common stock having an aggregate value of up to $35 million at an offering price of $6.03 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
16
Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.